PMID- 10915021
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20191025
IS  - 0753-3322 (Print)
IS  - 0753-3322 (Linking)
VI  - 54 Suppl 1
DP  - 2000 Jun
TI  - Enhanced sensitivity to alkylating agent in lymphocytes from patients with 
      multiple endocrine neoplasia type 1.
PG  - 187s-190s
AB  - Chromosome instability is known to be associated with certain autosomal recessive 
      cancer-prone disorders such as Fanconi's anemia. Multiple endocrine neoplasia 
      type 1 (MEN 1) is an autosomal dominant disorder characterized by development of 
      tumors in two or more endocrine organs, and chromosome instability in patients 
      with MEN 1 has been described. The clinical features of MEN 1 are, however, 
      distinct from other DNA instability syndromes except predisposition to tumors. 
      Therefore, we reevaluated chromosome instability in patients with familial MEN 1. 
      An increase in the frequency of chromosome aberrations was observed in MEN 1 
      patients but not in control subjects when peripheral mononuclear cells were 
      exposed to an alkylating agent, diepoxybutane (DEB). DEB reduced survival of 
      mononuclear cells in a dose-dependent manner in both MEN 1 patients and control 
      subjects, but this effect was more prominent in MEN I patients. There was no 
      apparent correlation between certain MEN1 gene mutations and sensitivity to DEB. 
      From these results, we conclude that hypersensitivity to alkylating agents exists 
      in patients with MEN 1. Molecular mechanisms of this phenomenon and relationship 
      to tumorigenesis in endocrine organs should be elucidated.
FAU - Itakura, Y
AU  - Itakura Y
AD  - Department of Aging Medicine and Geriatrics, Shinshu University School of 
      Medicine, Matsumoto, Japan.
FAU - Sakurai, A
AU  - Sakurai A
FAU - Katai, M
AU  - Katai M
FAU - Ikeo, Y
AU  - Ikeo Y
FAU - Hashizume, K
AU  - Hashizume K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Epoxy Compounds)
RN  - 60OB65YNAB (diepoxybutane)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*pharmacology
MH  - Cell Division/drug effects
MH  - Cell Survival/drug effects
MH  - Chromosome Aberrations
MH  - Chromosomes/*drug effects/ultrastructure
MH  - DNA, Neoplasm/drug effects
MH  - Epoxy Compounds/*pharmacology
MH  - Humans
MH  - Lymphocytes/*drug effects/ultrastructure
MH  - Monocytes/drug effects/ultrastructure
MH  - Multiple Endocrine Neoplasia Type 1/*pathology
EDAT- 2000/07/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/29 11:00
PHST- 2000/07/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/29 11:00 [entrez]
AID - S0753-3322(00)80041-4 [pii]
AID - 10.1016/s0753-3322(00)80041-4 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2000 Jun;54 Suppl 1:187s-190s. doi: 
      10.1016/s0753-3322(00)80041-4.